Aadi Bioscience reports Q3 FYARRO sales $6M (+40% YoY); net loss $16.3M; PRECISION1 interim on track for Dec 2023

Whitehawk Therapeutics, Inc.

2023-Q3 EPS reported -$1.84 revenue$18,028,000

FYARRO sales $6.0M in Q3 2023, up 40% YoY from $4.2M; net loss $16.3M vs $14.5M.
Cash, equivalents & investments $119.3M as of Sep 30, 2023, expected to fund operations into 2025.
PRECISION1 interim analysis on first third of patients (n=40) on track for mid-December 2023.
Dave Lennon appointed President and CEO in early October 2023.
Phase 2 trials initiated for endometrial cancer (nab-sirolimus + letrozole) and neuroendocrine tumors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Whitehawk Therapeutics, Inc. reported the quarter ended September 30, 2023 results: revenue $6.0 million, net income $16.3 million.

Period: the quarter ended September 30, 2023
Revenue: $6.0 million
Net income: $16.3 million
Result: reported results

Exact text from the filing

total revenue resulting from sales of FYARRO for the quarter ended September 30, 2023, was $6.0 million

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Whitehawk Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-037882

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.